Associations between depressive symptoms and inflammatory/hemostatic markers in women during the menopausal transition

Karen A. Matthews, Laura L. Schott, Joyce Bromberger, Jill Cyranowski, Susan A. Everson-Rose, Mary Fran Sowers

Research output: Contribution to journalArticlepeer-review

73 Scopus citations

Abstract

OBJECTIVE: To test whether depressive symptoms are related to inflammatory and hemostatic markers in women approaching menopause. METHODS: A total of 3292 women enrolled in the Study of Women's Health Across the Nation (SWAN) were followed for five years and had measures of Center for Epidemiologic Studies-Depression and high sensitivity C-reactive protein, Factor VIIc, fibrinogen, plasminogen activator inhibitor Type 1(PAI-1), and tissue-type plasminogen activator antigen (tPA-ag) up to four times during the follow-up period. Women were pre- or early perimenopausal status at study entry and were of Caucasian, African American, Hispanic, Japanese, or Chinese race/ethnicity. RESULTS: Unadjusted longitudinal mixed regression models showed that over a 5-year period, higher depressive symptoms were related to higher fibrinogen, PAI-1, and tPA-ag levels, all p < .0001. Taking into account health history, medication use, ethnicity, aging, and menopausal status, the depressive symptoms were related to fibrinogen, p < .01, and PAI-1, p < .05. Depressive symptoms were related only to fibrinogen in models that also included body mass index, p < .05. CONCLUSIONS: Depressive symptoms may be associated with cardiovascular risk in perimenopausal women in part through hypercoagulability. This is the first study to test the association of depressive symptoms and hemostatic and inflammatory markers across time.

Original languageEnglish (US)
Pages (from-to)124-130
Number of pages7
JournalPsychosomatic medicine
Volume69
Issue number2
DOIs
StatePublished - 2007

Keywords

  • Depression
  • Hemostatis
  • Inflammation
  • Longitudinal
  • Menopause
  • Women

Fingerprint

Dive into the research topics of 'Associations between depressive symptoms and inflammatory/hemostatic markers in women during the menopausal transition'. Together they form a unique fingerprint.

Cite this